Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Monday morning. The firm issued a hold rating on the stock.

Other equities analysts have also issued reports about the stock. Lake Street Capital started coverage on shares of Ekso Bionics in a report on Monday, June 24th. They issued a buy rating and a $2.50 price target on the stock. HC Wainwright reissued a buy rating and issued a $10.00 price objective on shares of Ekso Bionics in a research report on Tuesday, July 30th.

Ekso Bionics Trading Down 1.6 %

Shares of NASDAQ EKSO opened at $1.20 on Monday. Ekso Bionics has a 1-year low of $0.62 and a 1-year high of $3.13. The business has a fifty day moving average price of $1.13 and a 200 day moving average price of $1.22. The stock has a market capitalization of $21.81 million, a P/E ratio of -1.24 and a beta of 1.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, July 29th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The firm had revenue of $4.95 million for the quarter, compared to analysts’ expectations of $5.34 million. During the same period in the previous year, the company posted ($0.31) earnings per share. Equities research analysts expect that Ekso Bionics will post -0.42 EPS for the current fiscal year.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is owned by institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.